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Abstract Cystathionine beta-synthase (CBS) deficiency is a
rare inherited disorder in the methionine catabolic pathway, in
which the impaired synthesis of cystathionine leads to accu-
mulation of homocysteine. Patients can present to many dif-
ferent specialists and diagnosis is often delayed. Severely af-
fected patients usually present in childhood with ectopia
lentis, learning difficulties and skeletal abnormalities. These
patients generally require treatment with a low-methionine
diet and/or betaine. In contrast, mildly affected patients are
likely to present as adults with thromboembolism and to re-
spond to treatment with pyridoxine. In this article, we present
recommendations for the diagnosis and management of CBS
deficiency, based on a systematic review of the literature.
Unfortunately, the quality of the evidence is poor, as it often
is for rare diseases. We strongly recommend measuring the
plasma total homocysteine concentrations in any patient
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This article makes recommendations for the diagnosis and management
of CBS deficiency, based on a systematic review of the literature.
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whose clinical features suggest the diagnosis. Our recommen-
dations may help to standardise testing for pyridoxine respon-
siveness. Current evidence suggests that patients are un-
likely to develop complications if the plasma total homo-
cysteine concentration is maintained below 120 μmol/L.
Nevertheless, we recommend keeping the concentration
below 100 μmol/L because levels fluctuate and the com-
plications associated with high levels are so serious.
Abbreviations
AA Amino acid
CBS Cystathionine beta-synthase
D Dioptres
DBS Dry blood spots
DEXA Dual energy X-ray absorptiometry
EEG Electroencephalography
E-HOD European network and registry for
homocystinurias and methylation defects
GDG Guideline Development Group
Hcy Homocysteine
fHcy Free homocystine
tHcy Total homocysteine
L-AA L-amino acid
Met Methionine
MRI Magnetic resonance imaging
NBS Newborn screening
PKU Phenylketonuria
QoL Quality of life
RCT Randomised clinical trial
SAM S-adenosylmethionine
SAH S-adenosylhomocysteine
SIGN Scottish Intercollegiate Guideline Network
WHO/FAO/
UNU
World Health Organization/Food and
Agriculture Organization of the United
Nations/United Nations University
Introduction
Cystathionine beta-synthase (CBS) deficiency is a rare inherited
disorder, also known as classical homocystinuria (OMIM
236200). Homocysteine (Hcy) is a non-structural amino acid
(AA) that is formed in the catabolic pathway for the essential
AA, methionine (Met). CBS deficiency impairs the conversion
of Hcy to cystathionine and leads to its accumulation.
Patients with CBS deficiency show a wide spectrum of
severity and age at presentation. Some patients have a severe
childhood-onset multisystem disease, whilst others are
asymptomatic into adulthood. The main clinical features are
dislocation of the optic lenses, osteoporosis and a ‘marfanoid’
habitus, learning difficulties and a predisposition to thrombo-
embolism. Other causes of hyperhomocysteinemia include
inborn errors of Hcy remethylation, vitamin deficiencies (es-
pecially B12), renal insufficiency and medication.
Prevalence
CBS deficiency occurs worldwide but the prevalence varies
widely depending on ethnicity and the method of ascertain-
ment. The true population frequency is unknownwith estimates
ranging from 1:1800 to 1:900,000 based on birth incidence of
patients detected by newborn screening and/or estimates from
clinically ascertained patients (Mudd et al 1995; Zschocke et al
2009; Gan-Schreier et al 2010). The highest incidence has been
reported in Qatar (1:1800), where there is a high rate of con-
sanguinity and a founder effect, with a carrier frequency of
approximately 2 % (Zschocke et al 2009; Gan-Schreier et al
2010). Several molecular epidemiological studies in European
populations analysed frequency of heterozygotes for selected
mutations with subsequent calculation of the expected popula-
tion frequency of homozygotes (Gaustadnes et al 1999; Refsum
et al 2004a, b; Janosik et al 2009). These studies indicate that
the prevalence may have been underestimated, however, the
data also suggest that some homozygotes for mutation
c.833 T >C may be asymptomatic (Skovby et al 2010).
Biochemistry
The pathways of Met metabolism are shown in Fig. 1. Met is
converted to Hcy via S-adenosylmethionine (SAM) and S-
adenosylhomocysteine (SAH), releasing a methyl group
which is used in numerous methylation reactions. Glycine
N-methyltransferase acts on any excess SAM that is not used
in these reactions. Hcy can be converted back to Met by the
remethylation pathway. The methyl-group donor can either be
5-methyltetrahydrofolate (catalysed by methionine synthase,
with methylcobalamin as a cofactor) or betaine (especially in
patients treated with this drug). Alternatively, Hcy is irrevers-
ibly metabolised to cysteine by the transsulfuration pathway.
This starts with condensation of Hcy and serine to form
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cystathionine, catalysed byCBS. Cystathionine is subsequent-
ly cleaved by cystathionine γ-lyase to form cysteine and 2-
oxobutyrate. Cysteine can be further converted to taurine or to
inorganic sulfate via hydrogen sulfide.
CBS is expressed predominantly in liver, pancreas, kidney
and brain. Its catalytic domain binds heme and the cofactor
pyridoxal 5′phosphate, in addition to its substrates; the regu-
latory domain binds SAM as an allosteric activator.
Hcy contains a thiol (–SH) group that reacts readily with
other thiol groups. Hcy is, therefore, present in plasma in a
variety of chemical forms (Fig. 2). These include the free
reduced form (1 %), disulfides (homocystine and mixed
disulfides with cysteine or other thiols, in total about 30 %)
and protein-bound species (about 70 %) (Fowler and Jakobs
1998; Rasmussen andMoller 2000). The sum of the free and all
bound Hcy species is defined as total homocysteine (tHcy).
Cysteine also contains a thiol group and is present in different
reduced and oxidised forms including mixed disulfides and
protein-bound species. The binding capacity of plasma proteins
is limited and grossly elevated concentrations of homocysteine
lead to a decrease in plasma total cysteine. In CBS deficiency,
diminished cysteine production via the transsulfuration path-
way may also contribute to low cysteine concentrations.
Pathogenesis
The pathophysiology of CBS deficiency is not fully under-
stood. As well as the accumulation of Hcy, the defect leads to
increased concentrations of SAH, enhanced remethylation to
methionine, and depletion of cystathionine and cysteine.
Raised Hcy concentrations modify sulfhydryl groups on pro-
teins and interfere with the cross-linking of sulfhydryl groups in
proteins such as elastin; this is thought to cause the lens dislo-
cation and skeletal abnormalities. Raised Hcy concentrations
also alter intracellular signaling and cause endoplasmic reticu-
lum stress with endothelial dysfunction (Schienle et al 1995;
Lai and Kan 2015); these mechanisms together with impaired
thrombolysis may be responsible for thromboembolism and
vascular disease (Schienle et al 1994). Increased SAH impairs
methylation reactions and decreased cystathionine and cysteine
are associated with apoptosis, oxidative stress and alterations of
structural proteins such as fibrillin, which may contribute to
connective tissue abnormalities. Altered synthesis of hydrogen
sulfide may also contribute to the pathophysiology.
Methodology and objectives
Aims
This guideline aims to be a practical guide to the recognition,
diagnosis and management of CBS deficiency. It is designed
to be used by healthcare professionals who encounter this
condition, including paediatricians, physicians, geneticists,
biochemists, dietitians and psychologists. The guideline aims
to consider all patients with CBS deficiency, though some
sections will only apply to subgroups. Unfortunately, for
many issues there is a lack of high quality evidence and prac-
tice varies considerably. Even for these issues, standardisation
may bring advantages (e.g. for testing pyridoxine respon
siveness).
Guideline development
The guideline was written as part of the European network and
registry for homocystinurias and methylation defects (E-
HOD). A Guideline Development Group (GDG) was con-
vened, including paediatricians, adult physicians, dietitians,
biochemists, a clinical geneticist and a statistician. At the first
meeting, in November 2013, methodology was agreed to en-
sure standardised literature evaluation, the key questions were
decided and working groups were established to focus on
these topics. Subsequently, GDG members undertook a sys-
tematic literature review. Statements and supporting evidence
were prepared and discussed with the full group at two further
meetings, in July 2014 and April 2015. Further revision was
made following comments from a patient support group rep-
resentative (Tara Morrison, Director and Chair of HCU
Network Australia) and two highly renowned external re-
viewers (James V. Leonard and Bridget Wilcken).
Systematic literature review and evidence grading
The methodology used for collecting the evidence base for this
guideline is essentially that used by the Scottish Intercollegiate
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Fig. 1 Pathways of methionine metabolism. SAM, S-adenosylmethionine;
SAH, S-adenosylhomocysteine; THF, tetrahydrofolate; MeCbl,
methylcobalamin. 1, cystathionine beta-synthase; 2, methionine
adenosyltransferase I/III; 3, methionine adenosyltransferase II; 4, glycine N-
methyltransferase; 5, numerous methyltransferases; 6, S-
adenosylhomocysteine hydrolase; 7, methionine synthase; 8, betaine-
homocysteine methyltransferase; 9, Serine hydroxymethyltransferase; 10,
methylenetetrahydrofolate reductase; 11, cystathionine gamma-lyase
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Guideline Network (SIGN, http://www.sign.ac.uk). A systematic
literature review on CBS deficiency from the time of description
until December 2013 was carried out, mainly using Pubmed;
literature published after 2013 was added as needed. Relevant
papers were each evaluated by a minimum of two GDG
members. Evidence levels were classified in accordance with
the SIGN methodology (Table 1) and recommendations given
in the guideline were graded depending on their level of evidence
(Table 2).
Recommendations
Recommendations are organised as 41 separate statements. In the
following sections, each statement (in italics) precedes the expla-
nation and data used to craft the statement.
Clinical presentation
Clinical features (statement #1: grade of recommendation B)
There is a wide spectrum of severity, from individuals who are
currently asymptomatic to those with severe multi-system
disease, with a wide range of ages at presentation. The phe-
notype broadly relates to pyridoxine-responsiveness. Four
main organs/systems can be involved:
EYE: ectopia lentis and/or severe myopia
Skeleton: excessive height and length of the limbs
(‘marfanoid’ habitus) , osteoporosis and bone
deformities, such as pectus excavatum or carinatum,
genu valgum and scoliosis
Plasma  proteins 
Hcy-SH
Hcy-S-S-Hcy
Hcy-S-S-R
Hcy-S-S-Cys
Cys-SH
TOTAL CYSTEINE
TOTAL HOMOCYSTEINE
Cys-S-S-R
FREE HOMOCYSTINE
Cys-S-S-Cys
FREE CYSTINE
FREE CYSTEINE
HOMOCYSTEINE-
CYSTEINE MIXED 
DISULFIDE
PROTEIN 
BOUND 
CYSTEINE
FREE HOMOCYSTEINE
PROTEIN 
BOUND 
HOMOCYSTEINE
OTHER CYSTEINE 
MIXED DISULFIDES
OTHER 
HOMOCYSTEINE 
MIXED 
DISULFIDES
Fig. 2 Various forms of
aminothiols in plasma. Hcy-SH,
free homocysteine; Cys-SH, free
cysteine; Hcy-S-S-Hcy, free
homocystine; Cys-S-S-Cys, free
cystine; Hcy-S-S-Cys, mixed
disulfide; Hcy-S-S-R and Cys-S-
S-R, homocysteine and cysteine
bound to other thiols
Table 1 SIGN methodology
Evidence
level
Criteria
1++ High quality meta-analyses, systematic reviews of
randomised control trials (RCTs), or RCTs with a very
low risk of bias.
1+ Well conducted meta-analyses, systematic reviews of
RCTs, or RCTs with a low risk of bias.
1- Meta-analyses, systematic reviews or RCTs, or RCTs with
a high risk of bias.
2++ High quality systematic reviews of case-control or cohort
studies or high quality case control or cohort studies with
a very low risk of confounding bias, or chance and a high
probability that the relationship is causal.
2+ Well conducted case-control or cohort studies with a low
risk of confounding, bias, or chance and a moderate
probability that the relationship is causal.
2- Case-control or cohort studies with a high risk of
confounding, bias, or chance and a significant risk that
the relationship is not causal.
3 Non-analytic studies, e.g. case reports, case series.
4 Expert opinion.
Table 2 Grading according to SIGN
Grade of
recommendation
Criteria
A If level 1 evidence was found (never in this study)
B If level 2 evidence was found
C If level 3 evidence was found (mainly non-analytical
studies such as case reports and case series)
D If level 4 evidence was found (mainly expert
opinion)
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Central nervous system: developmental delay/intellectu-
al disability, seizures, psychiatric and behavioural prob-
lems and extrapyramidal signs
Vascular system: thromboembolism
Patients with CBS deficiency vary markedly in their
symptoms, age of onset and rate of progression of clinical
signs (Schimke et al 1965; Mudd et al 1985; Picker and
Levy 1993; de Franchis et al 1998). The severe end of the
spectrum, with multi-system disease, was described in early
reports (Carson et al 1965; Schimke et al 1965).
Subsequently, connective tissue, neuro-psychiatric and vas-
cular presentations have been recognised (Kelly et al 2003;
Linnebank et al 2003; Magner et al 2011; Zaidi et al 2012;
Karaca et al 2014).
Pyridoxine-responsive patients generally have a milder
phenotype and a later onset than the pyridoxine-
unresponsive ones (Mudd et al 1985; Abbott et al 1987).
At the mildest end of the spectrum, there is a large group
of patients who are extremely sensitive to pyridoxine, often
achieving normal tHcy levels on small doses. It is likely that
many of these patients remain asymptomatic throughout life,
especially those homozygous for the p.I278T mutation
(Skovby et al 2010). Others present as adults with thrombo-
embolism; a few have ectopia lentis but most have no other
complications. For these patients, the most relevant sections
of the guideline are 3A, 3B1-7, 3D, 3I3, 3 J and 3 K. The
diagnosis is often missed in these patients and the group has
been under-represented in most series, including the classical
description of the natural history (Mudd et al 1985). For this
reason, it is unknown what proportion of pyridoxine-
responsive patients develop complications.
Eye: ectopia lentis (dislocation of the lenses) is the ocular
hallmark of the disease. Without treatment, it usually occurs
during childhood, at least in pyridoxine unresponsive patients.
It may be preceded by progressive myopia (Mudd et al 1985;
Picker and Levy 1993).
Skeleton: patients tend to have excessive height and
limb length (dolichostenomelia and arachnodactyly) and
are prone to osteoporosis, at least after childhood.
Various bone deformities and abnormal X-ray findings
may also be present (Brenton 1977).
Central nervous system: intellectual, psychiatric and
behavioural problems are all common, especially in pyr-
idoxine unresponsive patients (Abbott et al 1987; El
Bashir et al 2015). Without treatment, approaching
90 % pyridoxine unresponsive patients have learning
difficulties (Mudd et al 1985). Seizures and extrapyra-
midal signs are also quite frequent features.
Vascular system: thromboembolism is the major cause
of morbidity and early death. Venous thrombosis is more
common than arterial but it can affect any part of the body
(Mudd 1985; Magner et al 2011; Karaca et al 2014).
Common presentations (statement #2: grade
of recommendation B-C)
Children are more likely to present with developmental delay
and ectopia lentis. Adults are more likely to be diagnosed
following vascular events. Most manifestations, however,
can occur at almost any age.
Patients with CBS deficiency can present to a wide range of
specialists, including pediatricians, ophthalmologists,
haematologists, neurologists, psychiatrists, orthopedic sur-
geons, cardiologists, vascular specialists and clinical geneti-
cists (Mudd et al 1985; Cruysberg et al 1996). Ocular findings
and developmental delay are important clinical signs in chil-
dren that may lead doctors to suspect CBS deficiency. Ectopia
lentis is particularly suggestive and should alert any ophthal-
mologist to this diagnosis. The diagnosis should also be con-
sidered if there is severe or rapidly progressing lenticular my-
opia. Vascular complications, such as cerebral venous sinus
thrombosis, can occur in childhood (Mudd et al 1985; Karaca
et al 2014) but vascular presentations without other features
are much more frequent in adulthood (Mudd 1985; Kelly et al
2003; Linnebank et al 2003; Magner et al 2011).
Differential diagnosis (statement #3: grade
of recommendation B)
The differential diagnosis of the presenting features is very
broad and includes Marfan syndrome and prothrombotic
disorders.
Severely affected patients with CBS deficiency share some
clinical features with Marfan syndrome, including tall slender
body habitus, arachnodactyly, lens dislocation and myopia
(Schimke et al 1965). Other genetic conditions associatedwith
non-traumatic lens dislocation include Weill Marchesani syn-
drome, Ehlers Danlos syndrome and sulfite oxidase deficien-
cy (Sadiq and Vanderveen 2013). To ensure that a treatable
diagnosis is not missed, CBS deficiency should be excluded in
all cases by measuring plasma tHcy.
There are a wide range of causes for thromboembolism,
psychiatric problems and intellectual disability. CBS deficien-
cy should be considered in the differential diagnosis, even if
the patient shows no other clinical features of classical
homocystinuria (Cruysberg et al 1996).
Diagnosis
Biochemical diagnosis (statement #4: grade
of recommendation C)
Plasma total homocysteine (tHcy) should be the frontline test
for diagnosis of CBS deficiency. Plasma free homocystine
(fHcy) only becomes detectable at tHcy concentrations above
approximately 50-60 μmol/L; its measurement is not
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recommended because of i ts low sensi t iv i ty and
reproducibility, and the demanding pre-analytical require-
ments. In untreated patients with CBS deficiency, tHcy con-
centrations are usually above 100 μmol/L but they may be
lower. The diagnosis is very likely if elevated tHcy is accom-
panied by high or borderline high plasma Met concentrations
and further supported if sensitive methods demonstrate low
plasma cystathionine concentrations with an increased Met-
to-cystathionine ratio.
CBS deficiency is characterised biochemically by an ac-
cumulation of Hcy, decreased synthesis of cystathionine
and cysteine and usually by increased Met (Orendac et al
2003; Stabler et al 2013). However, the classical pattern is
not always observed in all variants of CBS deficiency
(Stabler et al 2013).
Two indices of plasma homocysteine levels have been
widely used, the free homocystine (fHcy)—the concentration
of non-protein-bound disulfide homocystine—and the total
homocysteine (tHcy)—the sum of all free and bound homo-
cysteine species after treating plasma with a reducing agent
(see Fig. 2 for the different Hcy pools). Measurement of fHcy
has been possible since the 1960s, whereas tHcy has only been
widely available since the late 1990s. The plasma fHcy deter-
mined by an AA analyser is an insensitive marker of CBS
deficiency as it only becomes detectable once tHcy exceeds
approximately 50-60 μmol/L (Moat et al 1999; see below for
a larger study). In addition, this test is unreliable because the
fHcy continues to bind to plasma proteins in vitro unless rapid
deproteinization is carried out and meticulous pre-analytical
measures have been observed. Thus, determination of plasma
fHcy is no longer recommended for diagnosis or monitoring.
Measurement of urinary disulfide homocystine is even less
sensitive as this only becomes detectable once plasma tHcy
exceeds approximately 150 μmol/L (Moat et al 1999).
Figure 3 shows the relationship between plasma tHcy and
fHcy in a longitudinal study of 46 patients from a single centre.
In plasma samples with fHcy below the detection limit, the tHcy
concentration varied widely, with 5th and 95th centiles of 17 and
97 μmol/L, respectively. Segmented linear regression analysis
indicates that one would expect free homocystine to be present
when the tHcy concentration is above approximately 55μmol/L.
A fHcy concentration of 5 μmol/L corresponds to tHcy concen-
tration of approximately 88 μmol/L; below this concentration,
many amino acid analysers cannot quantify fHcy.
In untreated patients with CBS deficiency, plasma tHcy ex-
ceeds the upper limit of the reference range (which is generally
between 10 and 15 μmol/L, though it varies with age and meth-
od of analysis); tHcy concentrations are typically above
100 μmol/L but considerably lower concentrations may be
found in patients with mild variants of CBS deficiency (Kozich
and Kraus 2001; Refsum et al 2004a, b; Bermudez et al 2006;
Stabler et al 2013). The median tHcy in a cohort of 25 CBS
deficient patients was 125 μmol/L with a range of 16-281
(Stabler et al 2013). Indeed, plasma tHcy concentrations may
be normal in pyridoxine-responsive patients if they are receiving
even low doses of pyridoxine in vitamins and food supplements.
Further biochemical support for CBS deficiency can be
obtained by analysing plasma methionine (Met) and cystathi-
onine, the latter by sensitive LC-MS/MS or GC-MS/MS
methods. Patients with CBS deficiency have low to low nor-
mal cystathionine (reference range typically between 0.05-
0.08 and 0.35-0.5 μmol/L) and high to high normal methio-
nine concentrations (reference range typically between 12-15
and 40-45 μmol/L) with a grossly abnormal ratio of these two
metabolites. In contrast, genetic and nutritional disorders of
Hcy remethylation lead to raised plasma cystathionine and
low or low normal methionine concentrations (Orendac et al
2003; Stabler et al 2013; Bartl et al 2014).
Maximizing the sensitivity of biochemical testing (statement
#5: grade of recommendation C)
The diagnosis can be masked in patients with mild disease
who are taking pyridoxine or pyridoxine-fortified multivita-
mins and foods prior to biochemical testing.
The major confounder that may mask the biochemical hall-
marks of CBS deficiency is the intake of pyridoxine. Decreases
in the tHcy concentration occur after pharmacological doses of
pyridoxine in a substantial proportion of CBS deficient patients
(Mudd et al 1985; Wilcken and Wilcken 1997; Magner et al
2011). In pyridoxine-responsive patients with some specific mu-
tations (e.g. p.P49L), physiological doses of pyridoxine as low as
2 mg per day in an adult may decrease the tHcy concentrations
into the reference range (Stabler et al 2013). Since pyridoxine
is contained in many vitamin supplements as well as in
fortified foods and drinks, it is important to avoid intake
of any pyridoxine supplements for at least 2 weeks be-
fore sampling plasma for tHcy measurement, although
occasionally a wash-out period of up to 1-2 months
may be needed (Orendac et al 2003; Stabler et al 2013).
Pre-analytical requirements for biochemical testing
(statement #6: grade of recommendation B)
Plasma should ideally be separated from whole blood within
one hour of venepuncture and then can be stored at 4 °C for
up to 1-2 weeks prior to analysis. Although many factors
affect the physiology and measurement of tHcy, including
sample separation and storage, most are unlikely to influence
the diagnosis of CBS deficiency. Total homocysteine measure-
ment in dried blood spots (DBS) can be used as a screening
test for CBS deficiency if adequate plasma processing is not
possible.
The recommended blood sample handling for measuring
plasma tHcy is as follows. Venous blood should be drawn into
an anticoagulant specified by the laboratory. This is usually
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EDTA but some laboratories use heparin or citrate tubes. The
sample should be centrifuged within 1 hour if stored at room
temperature since red blood cells generate Hcy at a rate of
about 1-2 μmol/L/hr in unseparated whole blood (Refsum
et al 2004a, b) or within 8 hours if blood with anticoagulants
is stored at 4 °C; alternatively, serum may be used (Refsum
et al 2004a, b). After centrifugation the tHcy in plasma or
serum is stable for at least 4 days at room temperature, for
several weeks at 4 °C and several years at -20 °C (Refsum
et al 2004a, b). Whilst strict observation of pre-analytical
conditions may be important for research studies, differ-
ences in plasma tHcy concentrations due to suboptimal
pre-analytical procedures or diurnal variation, fed state,
pregnancy or posture are relatively minor and unlikely
to compromise the diagnosing of CBS deficiency in
typical cases (Refsum et al 2004a, b).
Fig. 3 Relationship between plasma total homocysteine and free
homocystine. Figure 3a shows the simultaneous tHcy and fHcy
measurements in 3522 plasma samples collected from 46 Irish patients
with CBS deficiency. Blood samples were obtained at the time of routine
clinic visits. Plasma was separated within 15 minutes after collection and
a 150 μL aliquot of plasma was immediately deproteinised by addition of
15 μL of 35 % sulphosalicylic acid; fHcy was measured by ion-exchange
chromatography with ninhydrin detection. tHcy was measured on the
aliquot of neat plasma by ion-exchange chromatography with ninhydrin
detection following incubation with 2.5 % dithiothreitol. Segmented lin-
ear regression analysis was used because fHcy could not be quantified
accurately below 5 μmol/L. The black point shows the model’s estimate
of the tHcy concentration at which fHcy will start to be present. The
shadowing around the regression line shows the 90 % confidence band
within which 90 % tHcy values lie for a given fHcy value. The section of
the graph for fHcy <15 μmol/L is expanded in Fig. 3b
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An alternative screening approach for determining tHcy is
the analysis of DBS obtained by sampling capillary or venous
blood on cards used in neonatal screening (McCann et al
2003; Bowron et al 2005; Turgeon et al 2010; Alodaib et al
2012; Bartl et al 2014). This is especially useful in clinical
situations when pre-analytical and sample transport conditions
cannot be met. Laboratories need to establish a local reference
range for tHcy concentrations in DBS, which are 30-40 %
lower compared to plasma, due to lower concentration of
tHcy in erythrocytes. tHcy levels are stable for a week at room
temperature but a 9 % decrease was observed after 28 days
(Bowron et al 2005; Bartl et al 2014).
Other causes of hyperhomocystinaemia (statement #7: grade
of recommendation C)
Other causes of hyperhomocystinaemia include renal failure,
nutritional vitamin B12 and folate deficiencies and genetic
disorders of vitamin B12 absorption or the Hcy remethylation
pathway. Decreased or low normal plasma Met, elevated
plasma cystathionine and/or elevated plasma or urinary
methylmalonic acid concentrations suggest causes of hyper-
homocysteinemia other than CBS deficiency.
Increased plasma tHcy concentrations are not specific for
CBS deficiency as there are many other genetic, nutritional
and pharmacological factors as well as several diseases asso-
ciated with tHcy elevation (Refsum et al 2004a, b).
Confirmation of CBS deficiency (as specified below) should
be accompanied by excluding other causes of hyperhomocys-
teinemia; the balance of these two approaches depends on the
degree of clinical suspicion of CBS deficiency.
Nutritional causes of hyperhomocysteinemia are common,
notably vitamin B12 deficiency and, less often, folate deficien-
cy. These should be excluded by measuring serum vitamin
B12 and/or transcobalamin II, plasma or urine methylmalonic
acid and serum folates (Refsum et al 2004a, b). Patients with
vitamin B12 deficiency can have tHcy up to 450 μmol/L
(Stabler 2013). Folate deficiency is particularly likely to cause
elevated tHcy concentrations in subjects who are homozygous
for the common c.677C > T variant in the MTHFR gene.
Renal failure is another frequent cause of hyperhomocystei-
nemia and should be excluded by measuring the serum creat-
inine concentration. The patient’s history is also important as
it may reveal other diseases associated with hyperhomocys-
teinemia or the administration of drugs such as nitrous oxide,
methotrexate and other folate antagonists (Rasmussen and
Moller 2000; Refsum et al 2004a, b).
Analysis of additional metabolites can usually distinguish
CBS deficiency from genetic and nutritional disorders in the
Hcy remethylation pathway. Low normal or decreased plasma
Met concentrations and elevated plasma cystathionine (deter-
mined by LC-MS/MS or GC-MS) indicate a disturbance in the
remethylation pathway; simultaneous elevation of
methylmalonic acid in plasma and/or urine suggests more
specifically disorders of vitamin B12 supply, transport or in-
tracellular metabolism with impaired synthesis of both
methylcobalamin and adenosylcobalamin (Stabler 2013;
Stabler et al 2013).
Confirmatory testing (statement #8: grade
of recommendation B-C)
CBS deficiency should be confirmed by measurement of cys-
tathionine synthase activity in fibroblasts or plasma and/or by
mutation analysis of the CBS gene. Neither technique can be
relied on to demonstrate abnormalities in all cases.
Confirmation of CBS deficiency cannot be based on a sin-
gle method as each technique gives normal results in some
patients with CBS deficiency. The gold standard for
confirming CBS deficiency is generally considered to be the
determination of cystathionine production from Hcy and ser-
ine in cultured fibroblasts using radioactive or deuterium la-
belled substrates (Kraus 1987; Smith et al 2012). The fibro-
blast CBS activity may, however, be normal in mild forms of
the disease, despite biochemical and clinical abnormalities
and mutations in the CBS gene. In one study, three of 13
CBS deficient patients had normal CBS activity in fibroblasts
(Mendes et al 2013). Recently two rapid stable isotope assays
have been developed for measuring activity of CBS released
from liver and other organs into plasma (Krijt et al 2011;
Alcaide et al 2015). Studies on patients with 27 different ge-
notypes showed that sensitivity of the plasma assay was
100 % for detecting pyridoxine non-responsive patients but
only 86 % for the pyridoxine responders. Sequencing of the
CBS gene is considered the gold standard in molecular diag-
nostics; however, pathogenic variants may not be detected in
one of the parental alleles in up to 7-10 % of CBS deficient
patients (Gaustadnes et al 2002; Magner et al 2011). In sum-
mary, if one of these techniques (enzyme or DNA analysis)
does not confirm a diagnosis of CBS deficiency the other test
should be done in a patient with metabolite abnormalities
suggestive of this disease.
Role of DNA analysis (statement #9: grade
of recommendation B)
Molecular genetic analysis of the CBS gene is helpful for the
confirmation of CBS deficiency and for carrier and prenatal
testing.
The reliability of DNA testing depends on the method,
technical quality and extent of analysed regions of the CBS
gene and on the nature of the underlying mutation (Katsanis
and Katsanis 2013). Technical pitfalls include the PCR step
that may amplify only one of the parental alleles, failure to
detect larger rearrangements and inadequate sequencing of
portions of the gene.
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Interpreting the results of mutation analysis is straightforward
if the genetic variant is already known and segregates with the
biochemical and/or clinical phenotype. However, novel variants
of unknown significance detected in genomic DNA may be dif-
ficult to interpret, especially if they affect RNA splicing and/or its
stability. Expression of mutants in heterologous systems may not
shed light on pathogenicity of missense variants, as many CBS
mutants exhibit normal or even supra-normal catalytic activity
and only subtle conformational changes can explain their patho-
genicity in vivo (Krijt et al 2011; Hnizda et al 2012).
Targeted mutation analysis in individuals at risk for genetic
variants segregating in the family is suitable for detecting het-
erozygotes and for prenatal testing using chorionic villi or
amniocytes.
Genotype-phenotype correlations (statement #10: grade
of recommendation C)
Over 160 disease causing genetic variants in the CBS gene
are known. For compound heterozygotes it is difficult to es-
tablish clear genotype/phenotype correlations. For a few mu-
tations commonly present in the homozygous state, however,
there are well established genotype/phenotype correlations
with good concordance between pyridoxine responsiveness
and a milder clinical phenotype.
As of January 2016, more than 900 CBS alleles in patients
of varied ethnic origin were characterised and 164 different
pathogenic genetic variants were observed (www.cbs.lf1.cuni.
cz). In some populations specific mutations have been
repeatedly detected such as the c.919G >A (p.G307S) in the
Irish (Yap 2012), the c.572C > T (p.T191M) in Spanish,
Portuguese and South Americans (Cozar et al 2011; Alcaide
et al 2015) and the c.1006C > T (p.R336C) in the Qatari pop-
ulation (Gan-Schreier et al 2010), all causing a severe pyri-
doxine non-responsive form of disease when inherited in the
homozygous state. In contrast, the commonest variant, c.833
T > C (p.I278T), has been detected in many European popu-
lations and patients from elsewhere who may have European
ancestry; when homozygous, this variant leads to a mild
pyridoxine-responsive type of CBS deficiency (Skovby et al
2010). Compound heterozygotes carrying the c.833 T > C (p.
I278T) variant at one allele are usually at least partially pyri-
doxine responsive but there are exceptions (www.cbs.lf1.cuni.
cz). Genotype/phenotype correlation has been established for
additional mutations in homozygous patients, however, such
correlations are difficult to infer in individuals who are com-
pound heterozygotes.
Prenatal diagnosis (statement #11: grade of recommendation
C-D)
Molecular analysis is the preferred technique for the first-
trimester prenatal diagnosis if the mutations in both parents
are known. Alternatively, enzyme analysis can be performed
in cultured amniocytes but not in chorionic villi. Pre-
implantation genetic testing is feasible.
Targeted mutation analysis in native or cultured chorionic villi or in
amniocytes canbeperformed if themutationsareknownin thepropositus
in the family and in both parents. If themutations in the family at risk are
unknown (or known in only one parent) prenatal testing is feasible by
determiningCBSactivity inculturedamniocytes.Nativechorionicvilli are
not suitable for enzymatic diagnosis due to very low activity in controls
(Fowleretal1989)andculturedchorionicvillihavealsoprovedunsuitable
(Kraus JP, personal communication).
Newborn screening (statement #12: grade of recommendation
C)
Newborn screening for CBS deficiency can be performed by
detecting elevated Met,Met-to-phenylalanine ratio and/or hy-
perhomocysteinemia in DBS although tHcy has only excep-
tionally been used as a primary marker. Sensitivity of Met as a
primary marker for pyridoxine non-responsive CBS deficien-
cy is limited and inversely related to the chosen cut-off con-
centrations of Met. For the pyridoxine-responsive form of the
disease, sensitivity is largely unknown and probably very low.
Specificity of Met as a primary marker may be substantially
increased by analysing tHcy as a second tier marker and
calculating the Met/tHcy ratio.
Long-term experience with newborn screening (NBS) for
CBS deficiency has been obtained in a limited number of
screening programmes by detecting increased Met concentra-
tion in DBS (Chace et al 1996; Mudd 2011). Due to the longer
analytical procedure and higher costs, measurement of tHcy as
a primary NBS marker has been used so far only in Qatar
(Gan-Schreier et al 2010).Molecular genetic testing is feasible
and may be an option for high-risk populations with a limited
number of prevalent mutations although patients with muta-
tions not contained in the panel will be missed (Gan-Schreier
et al 2010). A detailed analysis of newborn screening for CBS
deficiency has been published recently (Huemer et al 2015).
While the median Met concentration of 103 μmol/L in
DBS of CBS deficient patients are substantially higher than
the median of 20 μmol/L in healthy neonates, individual Met
values may vary widely (McHugh et al 2011). The sensitivity
of Met for detecting newborns with CBS deficiency is not
exactly known and 20 %-50 % of pyridoxine non-responsive
cases may be missed (Naughten et al 1998; Gan-Schreier et al
2010). Although the pyridoxine responsive form of CBS de-
ficiency represented 44 % of patients in the largest cohort
reported so far (Mudd et al 1985), Met most likely fails to
detect the majority of pyridoxine responsive patients (Mudd
2011). Indeed, some experts have suggested that screening
detects even fewer pyridoxine-responsive cases and that some
cases originally thought to respond were incorrectly assigned.
Reducing the Met cut-off concentrations increases the
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detection rate of CBS deficiency and consequentlyMet cut-off
values ranging between 39 and 50 μmol/L have been pro-
posed to increase sensitivity (Turgeon et al 2010; McHugh
et al 2011). The sensitivity may also be increased by deter-
mining the Met/Phe ratio to adjust for protein intake.
Elevated blood methionine concentrations occur not only
in CBS deficiency but also in liver disease, methionine
adenosyltransferase I/III deficiency and several other inborn
errors of metabolism (Mudd 2011). Low specificity of Met as
the first tier analyte can be substantially improved by quanti-
fying tHcy as a second-tier marker (Turgeon et al 2010; Mudd
2011; Alodaib et al 2012). This approach can reduce the false
positive rate fivefold (Turgeon et al 2010) and data on tHcy in
DBS as a secondary marker showed a good sensitivity with
clear distinction between 31 CBS deficient patients (median
tHcy 40 μmol/L) and controls (6 μmol/L). In addition, calcu-
lating the Met/tHcy ratio may discriminate between CBS and
MATI/III deficiency, although more experience with this
marker is needed.
Family screening (statement #13: grade of recommendation
D)
When an index case is detected, screening of at-risk family
members should be offered using biochemical testing.
Since CBS deficiency is an autosomal recessive condition,
family members at risk for the disease should be tested by
measuring tHcy or, in exceptional cases, by molecular genetic
or enzymatic analysis.
Treatment targets
Clinical targets of therapy (statement #14: grade
of recommendation D)
For early diagnosed patients, treatment can realistically aim
to prevent all the complications of CBS deficiency, whilst
maintaining normal growth and nutrition and allowing the
patient normal opportunities for employment and family life.
For late-diagnosed patients, the aim is to prevent further
complications, especially thromboembolic disease.
The clinical outcomes have been studied extensively in
Irish, British and Australian patients with CBS deficiency de-
tected by NBS. These studies found that good compliance
with dietary treatment prevented ectopia lentis, osteoporosis
and thromboembolic events (Wilcken and Turner 1978;
Wilcken and Wilcken 1997; Yap and Naughten 1998; Yap
et al 2000; Yap et al 2001a, b, c); it also led to normal intelli-
gence. Thus, prevention of all recognised complications is a
realistic goal for early diagnosed patients with CBS deficien-
cy. The dietary treatment should not compromise growth and
nutrition. This should allow patients to achieve satisfying em-
ployment and to have a family if they wish.
Unless diagnosed by NBS or because of a family history,
patients will present with one of the complications of
homocystinuria. Children are often diagnosed following dis-
location of the optic lens, by which time they may have some
learning difficulties. Adults are usually diagnosed after a
thromboembolic event. For late-diagnosed patients, the main
aim is to prevent further complications; behavioural and intel-
lectual improvement has also been reported (Grobe 1980). A
major goal is to prevent thromboembolic disease, as this is the
commonest late complication (Wilcken and Wilcken 1997;
Yap et al 2001a, b, c).
Biochemical targets of therapy (statement #15: grade
of recommendation C)
Treatment aims to lower the plasma tHcy concentration to a
safe level whilst maintaining normal nutrition, including nor-
mal concentrations of methionine and other essential AA. In
pyridoxine-responsive patients the target for plasma tHcy
should be <50 μmol/L. This may not be achievable for pa-
tients that only show a partial response. In pyridoxine-
unresponsive patients, historical data suggests that good out-
comes can be achieved if plasma fHcy levels are maintained
below 11 μmol/L. This corresponds to a tHcy concentration of
about 120 μmol/L. We recommend keeping tHcy levels below
100 μmol/L but this may need revision when very long term
data become available. It is particularly important to remind
adolescents and young adults of the dire consequences of poor
compliance.
In general, the aim is to keep the Hcy concentration as close
to normal as possible. In patients who are fully-responsive to
pyridoxine, standard doses can lead to tHcy levels below
50 μmol/L (and sometimes within the normal range). Some
patients who are partially-responsive to pyridoxine may be
able to achieve a tHcy level below 50 μmol/L if they are also
on a low-Met diet; for others it is not a realistic goal. Excessive
Met restriction, with plasmaMet concentrations that are some-
times below the normal range, may impair growth and
neurodevelopmental progress in children.
The published Irish studies found that pyridoxine-
unresponsive patients had a normal IQ and no complications
if their lifetime median plasma fHcy concentration was less
than 11 μmol/L (Yap and Naughten 1998; Yap et al 2001a, b,
c). Some of these patients have subsequently suffered compli-
cations, especially thromboembolic events but these followed
poor control for many months. There have still been no com-
plications in those Irish patients detected by NBS, now aged
up to 43 years, whose plasma fHcy has consistently been less
than 11 μmol/L, or who have only had brief rises above this
for days or weeks (Crushell E and O’Sullivan S, personal
communication).
No long term data relating tHcy concentrations to outcome
have been published and it is not possible to predict the tHcy
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accurately from the fHcy due to the inherent variability in the
measurement of fHcy and the wide confidence interval, as
discussed above (see Biochemical diagnosis (statement #4: grade
of recommendation C)). Using segmented linear regression anal-
ysis on the data presented in Fig. 2, we estimate that a median
fHcy of 11μmol/L corresponds to amedian tHcy of 120μmol/L
(Fig. 3-inset). Thus, the Irish data suggest that patients may be
safe with plasma tHcy levels up to 120 μmol/L.
Within the GDG, there were minor differences of opin-
ion concerning target plasma tHcy concentrations for pa-
tients on dietary treatment. Some GDG members thought
the aim should be to keep tHcy concentrations below
120 μmol/L because there is evidence to support this;
lower target levels are hard to achieve consistently in
young adults and may even risk compromising nutrition.
Other GDG members favoured stricter targets (e.g. below
70 or 80 μmol/L), as there are fluctuations even in the
most compliant of patients and we still do not have very
long term outcome data. Following discussion, the GDG
thought it was reasonable to recommend keeping the plas-
ma tHcy concentration below 100 μmol/L; stricter control
may have benefits but this is unproven.
As discussed in Pre-analytical requirements for biochemi-
cal testing (statement #6: grade of recommendation B), tHcy
concentrations are lower in DBS. If these are used for moni-
toring, the target level should be adjusted appropriately (below
about 60-70 μmol/L, depending on the method used).
Particular efforts should be made to keep tHcy levels
in the target range in adolescents and young adults and
patients must be made aware of the dire consequences
of poor compliance. Thromboembolism is the main con-
cern; high tHcy levels at this age may also lead to lens
subluxation and possibly psychiatric issues.
Pyridoxine-responsive homocystinuria
Assessment of pyridoxine-responsiveness (statement #16:
grade of recommendation C-D)
To assess pyridoxine responsiveness after infancy, we recom-
mend giving 10 mg/kg/day pyridoxine up to a maximum of
500 mg/day for 6 weeks; the plasma tHcy concentration
should be measured at least twice before treatment and twice
on treatment. The test should not be done if the patient is
catabolic. The protein intake should be normal, folate supple-
ments should be given and vitamin B12 deficiency should be
corrected prior to testing. Patients who achieve plasma tHcy
levels below 50 μmol/l on pyridoxine are clearly responsive
and do not need any other treatment. If the tHcy falls >20%
but remains above 50 μmol/L, additional treatment should be
considered (i.e. diet and/or betaine). If tHcy falls by <20% on
pyridoxine, the patient is likely to be unresponsive.
Patients detected by newborn screening rarely respond to
pyridoxine and, in this group, we recommend using a relative-
ly high dose (100 mg/day) for a shorter period (2 weeks).
Pyridoxine responsiveness is often defined according to the
plasma concentration of homocysteine (or related measure-
ments) on treatment. Criteria have included tHcy <50 μmol/
L (Kluijtmans et al 1999), fHcy not detectable (i.e. approxi-
mately tHcy <55 μmol/L, as discussed above) (Yap et al
2001a, b, c), fHcy <10 μmol/L (Walter et al 1998) or total free
homocysteine (i.e. twice homocystine concentration plus
homocysteine-cysteine disulfide concentration) <20 μmol/L
(Wilcken and Wilcken 1997). Many patients, however, show
a partial response to pyridoxine (Brenton and Cusworth 1971)
and it should be continued in these patients. Additional treat-
ment is needed if there is a partial response and target levels
are not reached.
Various protocols have been used to test pyridoxine respon-
siveness (Mudd et al 1995; Wilcken and Wilcken 1997;
Walter et al 1998; Yap and Naughten 1998; Kluijtmans et al
1999; Yap et al 2001a, b, c). Our recommendation (Fig. 4)
takes account of physiological variation in tHcy levels and
the limited precision of measurements. Folate and vitamin
B12 deficiencies can impair the response to pyridoxine and
some patients take several weeks to achieve their full response
(Walter et al 1998; Yap et al 2001a, b, c).
Patients detected by newborn screening seldom respond
to pyridoxine (Morrow and Barness 1972; Wilcken and
Turner 1973; Kluijtmans et al 1999). Unpublished data from
the E-HOD registry, however, show that sensitive screening
strategies may detect more patients with the pyridoxine-
responsive form of homocystinuria than reported previous-
ly (Huemer and Kozich, unpublished). To avoid delaying
effective treatment, we recommend giving neonates a rela-
tively high pyridoxine dose (e.g. 100 mg/day) for at least
2 weeks, with measurement of the plasma tHcy at the end of
the first and second weeks. If a patient shows an equivocal
fall in Hcy, the trial should be continued for longer, to con-
firm that the fall is not just due to anabolism. If cystathio-
nine is measured, a rise in this metabolite provides extra
evidence for a genuine response to pyridoxine.
Adverse effects of pyridoxine (statement #17: grade
of recommendation D)
Peripheral neuropathy is the most important adverse effect of
pyridoxine. It has been reported in a number of patients treat-
ed with long-term high doses of pyridoxine >900 mg/day.
There is a high risk of peripheral neuropathy following
long-term treatment with pyridoxine doses above 900 mg/
day (Schaumburg et al 1983; Ludolph et al 1991, 1993), but
it has not been found in patients treated with less than 500 mg/
day (Cohen and Bendich 1986; Mpofu et al 1991; Yap et al
2001a, b, c). Reports of peripheral neuropathy with doses
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below 500 mg/day are unreliable (Parry and Bredesen 1985).
Withdrawal of pyridoxine has led to improvement of the neu-
ropathy in some patients (Schaumburg et al 1983).
Periods of apnoea and unresponsiveness have been report-
ed in a few neonates following large oral doses of pyridoxine
(500 mg/d) (Mudd et al 1995), as well as after intravenous
doses for pyridoxine dependent epilepsy. Rhabdomyolysis
has also been reported (Shoji et al 1998).
Recommended pyridoxine doses (statement #18: grade
of recommendation D)
For long-term treatment, the pyridoxine dose should be the
lowest that achieves the biochemical targets (plasma total
homocysteine <50 μmol/L). We recommend using doses up
to 10 mg/kg/day and avoiding doses above 500 mg/day.
Pyridoxine doses of 10-40 mg can achieve biochemical
targets in some patients with the p.P49L and p.I278T mu-
tations (Stabler et al 2013). Pyridoxine doses of 200 mg/
day or less can achieve the biochemical targets in many
other patients. Partially pyridoxine-responsive patients
need higher doses and additional treatment (betaine and/
or diet). The risk of peripheral neuropathy appears to be
low in adults with pyridoxine doses below 500 mg/day
(see Adverse effects of pyridoxine (statement #17: grade
of recommendation D)). In children, the safe dose is likely
to depend on body weight; there are few data but we
suggest using doses up to 10 mg/kg/day, with a maximum
of 500 mg/day.
Pyridoxine in non-responsive patients (statement #19: grade
of recommendation D)
There is no evidence that long-term pyridoxine is beneficial if
there is no biochemical response in a properly conducted test.
There is no evidence that pyridoxine has beneficial
effects independent of lowering Hcy concentrations.
Though there can be a delay in seeing the full response,
some response (i.e. >20 % decrease) should be seen
within two weeks in patients who are not deficient in
vitamin B12 or folate.
Role of vitamin B12 and folate supplementation (statement
#20: grade of recommendation D)
All patients should receive adequate folate supplementation.
Vitamin B12 should be monitored and supplemented if
deficient.
There are several reports of vitamin B12 and folate
deficiencies in patients with CBS deficiency (Smolin
et al 1981; Ishida et al 2001). This may be due to in-
creased flux through the remethylation pathway and use
of the cofactors, or inadequate intake of the vitamins in
patients on restricted diets. We recommend giving all pa-
tients low-dose folate supplements and monitoring their
vitamin B12 levels. High dose folate therapy may lead to
an additional benefit through enhancing the remethylation
pathway but may have side effects (Wang et al 2014).
Though it is clear that folate deficiency must be avoided,
there is little evidence concerning the optimal dose of
folate supplementation. In patients on dietary treatment,
folate and vitamin B12 supplements are generally included
in the Met-free L-AA supplement, and it is not clear
whether additional supplements are routinely required.
Dietary management
Approaches to dietary treatment (statement #21: grade
of recommendation C-D)
Dietary treatment should be considered for all patients with
CBS deficiency unless target Hcy levels are achieved entirely
by pyridoxine supplementation. Diet may be used either as a
sole treatment or adjunctive therapy along with pyridoxine
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Fig. 4 Proposal for assessing pyridoxine responsiveness after infancy.
The baseline must be stable and should be the average of at least two
separate measurements
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and/or betaine. Most pyridoxine-unresponsive patients re-
quire a diet that is very low in natural protein, with supple-
ments of a Met-free L-AA mixture. Lifelong treatment is
required.
Dietary management of CBS deficiency can be highly
successful. It should be considered for all pyridoxine un-
responsive patients and as additional treatment in individ-
uals who are partially pyridoxine responsive (Komrower
et al 1966; Perry et al 1966, 1968; Mudd et al 1985;
Pullon 1988; Walter et al 1998; Yap and Naughten 1998;
Lutteri et al 1999; Kabra 2002; Keating et al 2011; Schiff
and Blom 2012; Adam et al 2013; de Lonlay et al 2002).
Restricting intake of the essential AA, Met, reduces
the precursor load on the transsulfuration pathway,
thereby reducing Hcy production. In most pyridoxine-
unresponsive patients, the biochemical targets can only
be achieved by a diet that is very low in natural protein,
with supplements of a Met-free L-AA mixture. The ap-
proach is analogous to the management of phenylketon-
uria (PKU) for which there is a greater body of pub-
lished evidence.
There are very few reported complications with well
managed dietary treatment (Perry et al 1968), however
the diet is complex and difficult so poor adherence is
common (Lawson-Yuen and Levy 2006; Schiff and
Blom 2012). Problems can be reduced by starting die-
tary treatment in individuals as young as possible and
utilising the skills of an experienced metabolic dietitian
(Yap and Naughten 1998; Kabra 2002; Schiff and Blom
2012). Treatment for CBS deficiency must be continued
throughout life, as loss of biochemical control in later
life is associated with serious complications (Walter
et al 1998). Compliance with treatment often deterio-
rates, particularly in adolescence, as in other disorders
(Walter et al 1998). Initiating dietary restrictions in late
diagnosed individuals is more challenging than in neo-
nates but it can reduce the risk of further complications
and lead to improvement, for example in seizures and
behaviour (Holliday et al 1976; Walter et al 1998;
Garland et al 1999; Kabra 2002).
Additional treatment with betaine can help patients who
find it difficult to adhere to dietary restrictions and to attain
good metabolic control (see Betaine treatment). Betaine
lowers Hcy levels, potentially allowing an increase in Met
intake (Walter et al 1998). Met restriction in individuals treat-
ed with betaine can also prevent excessively raised Met levels
and the possible risks associated with these—see Side effects
of betaine (statement #28: grade of recommendation C-D)
(Pullon 1988; Garland et al 1999; Lawson-Yuen and Levy
2006). A recent European survey of pyridoxine unre-
sponsive patients found that a combination of dietary
restriction and betaine was the commonest treatment
(Adam et al 2013).
Methionine restriction (statement #22: grade
of recommendation D)
The level of Met or natural protein restriction required varies
and is determined for each patient according to their plasma
tHcy and Met concentrations.
The target plasma tHcy concentrations are discussed in
Biochemical targets of therapy (statement #15: Ggrade of rec-
ommendation C). The amount of Met that a patient can take
whilst achieving these levels depends on various factors, in-
cluding the degree of residual CBS enzyme activity, the re-
sponsiveness to pyridoxine, the use of betaine and the pa-
tient’s age and growth rate. The allowance of Met (or natural
protein) should be determined for each patient individually by
an experienced metabolic dietitian, based on their plasma Met
and tHcy levels.
Met is an essential AA and an adequate supply should be
ensured, particularly in growing children. There are, however,
no data for theMet requirement in patients with CBS deficien-
cy. Recommendations by theWHO cannot be used as they are
expressed for Met and cysteine combined (WHO et al 2007).
Close monitoring of plasmaMet levels and growth are needed
in patients with severe CBS deficiency, who require a lowMet
intake in order to achieve good biochemical control.
For infants diagnosed through NBS in the UK, the supply
ofMet/natural protein (from breast milk or formula) is stopped
(after the pyridoxine test) and a Met-free complete infant for-
mula is given for 2-4 days to reduce Hcy levels. Met in the
form of breast milk or infant formula is then introduced, di-
vided into several feeds, in conjunction with the Met-free
formula (Dixon et al 2015). UK guidelines recommend a
starting allowance of 90-120 mg Met/day (or 30 mg/kg/day
if weight <3 kg). TheMet allowance is then titrated against the
patient’s plasma tHcy levels. A potential management pathway
is shown at http://www.bimdg.org.uk/store/enbs//HCU_
D i e t e t i c _ M a n a g e m e n t _ P a t h w a y _ V 1 _
April_2015_215380_12052015.pdf.
Breast feeding has proven benefits for infants but there are
few published reports of its use in inherited metabolic diseases
other than PKU. An international survey reported five infants
with CBS deficiency who had received breast-feeds in com-
bination with a Met-free AA infant formula (MacDonald et al
2006a, b). The principles are the same as for breast-feeding in
PKU (Francis and Smith 1981). Measured volumes of a Met-
free infant formula are given prior to breast-feeds, thereby
limiting the amount of breast milk (and Met) taken.
Weaning should begin at the usual time and progress
through stages as normal. Naturally low protein foods or
manufactured low protein foods are introduced first.
Gradually the Met allowance of breast milk or standard for-
mula is replaced with protein/Met containing foods. Age ap-
propriate concentrated L-AA supplements are introduced at
appropriate times to ensure full protein requirements are met.
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For older children and adults, the diet is either based on
Met-restriction or natural protein-restriction. The Met-
restricted diet is calculated by estimating the daily Met intake,
whereas the protein-restricted diet is based on the intake of
natural protein and the assumption that 1 g of protein provides
a specific quantity of Met. For practical reasons, a combina-
tion of the two is often used (Adam et al 2013). In theory, the
Met-restricted diet is preferable because the Met content of
different foods varies relative to their protein content. There
are, however, limited data for the Met content of foods (Adam
et al 2013).
The introduction of dietary restriction is extremely difficult
in late diagnosed patients and is best done gradually. If a Met-
free L-AA supplement is likely to be required, this should be
started first to ensure nutritional adequacy whilst reducing the
Met/protein intake.
Role of L-AA mixtures (statement #23: grade
of recommendation D)
The majority of patients on dietary treatment require a low
Met diet with a cystine-enriched, Met-free L-AA supplement.
Some partially pyridoxine-responsive patients benefit from
milder protein restriction without Met-free L-AA supplements.
In CBS deficient individuals, the natural protein/Met al-
lowance from food may be too low to support a normal
growth rate in infants and children and to meet protein require-
ments in adults. In these instances a cystine-containing, Met-
free L-AA formula/supplement should be used. These are also
often supplemented with fat, carbohydrate and micronutrients
and are available in a variety of forms with age-specific mi-
cronutrient provision (Walter et al 1998). In a recent European
dietetic survey, all children <16 years were prescribed an age-
appropriate L-AA supplement (Adam et al 2013).
There are currently no specific recommendations for the
Met-free L-AA or total protein intake in CBS deficiency
(Adam et al 2013). The WHO/FAO/UNU (2007) recommen-
dations can be used to guide the total protein requirements
(WHO et al 2007) but PKU research suggests that higher
protein intakes than the WHO recommendations are required
to compensate for the sub-optimal bio-availability of L-AAs
in current preparations (MacDonald et al 2006a, b). It is rec-
ommended that the L-AA supplement is split into three to four
doses throughout the day to maximise nitrogen retention and
achieve appropriate growth (Acosta 2010).
It is important to avoid both inadequate and excessive in-
take of the L-AA supplement. Inadequate intake may be due
to being insufficiently prescribed or poor adherence and can
result in poor biochemical control, poor growth and malnutri-
tion (Walter et al 1998). Adherence to Met-free L-AA supple-
ments can be poor due to their taste.
Patients who are partially pyridoxine-responsive may
achieve target tHcy levels with a relatively mild protein
restriction and may not require Met-free L-AAs supplements.
Late-diagnosed pyridoxine-unresponsive patients are also
sometimes managed with a relatively mild protein restriction
and betaine, if they cannot adhere to a stricter diet. These
patients still require close monitoring of their nutritional status
and dietary intake.
Role of cysteine. (statement #24: grade of recommendation D)
In patients with severe deficiency, additional cystine supple-
mentation may be necessary but there is no evidence to guide
the level required.
Cysteine is normally formed from methionine via the
transsulfuration pathway. Cysteine is, therefore, a ‘condi-
tionally essential’ AA in CBS deficiency and low concen-
trations may contribute to the pathogenesis. Cysteine, like
Hcy, contains a thiol group and is present in different
reduced and oxidised forms. Since the binding capacity
of plasma proteins for thiols is limited, grossly elevated
Hcy concentrations lead to a decrease in plasma total cys-
teine, as often seen in poorly controlled patients. The em-
phasis should, however, be on improving Hcy control as
total cysteine levels increase when Hcy levels fall (see
also Fig. 2). Results should be interpreted in liaison with
the monitoring laboratory, as most laboratories measure
free (non-protein-bound) cystine concentrations, which
may be falsely low without prompt deproteinisation of
the blood samples (Hargreaves et al 2002). Total cysteine
measurement avoids these preanalytical complications but
it is not widely available.
Case reports suggest that cysteine deficiency can cause
poor weight gain and growth even in the presence of adequate
energy intake (Perry et al 1966). Cystine is added tomostMet-
free L-AA supplements but the quantities are sometimes no
greater than in supplements for other AA disorders, such as
PKU. It is not clear if this is sufficient. Cystine supplementa-
tion can be difficult to administer due to its poor solubility and
unpleasant taste.
Further research is needed addressing the accurate cysteine
levels in treated patients and whether additional L-cystine
supplementation improves the outcomes of patients with good
Hcy control.
Role of energy and micronutrient supplements (statement #25:
grade of recommendation D)
The diet should be nutritionally complete whilst being varied
and palatable, to optimise adherence.
It is important that energy requirements are met to ensure
optimal dietary protein utilisation as protein synthesis and
catabolism are energy dependent. National recommendations
for energy intake should be followed because the specific
energy requirement in CBS deficiency is unknown.
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Manufactured low protein foods are available and most
European metabolic centres use them to ensure adequate
energy intake in CBS deficiency (Adam et al 2013).
Studies in other metabolic disorders suggest that low
protein foods improve compliance with the diet and pal-
atability, although there is no specific evidence for this
in CBS deficiency.
There are no established micronutrient requirements
for CBS deficiency and normal population reference
values should be used as a guide. If micronutrients are
not included within the L-AA supplement, additional
supplements may be required. The intake should be
assessed regularly, particularly for calcium, and micro-
nutrient status should be monitored.
Many L-AA supplements now contain long chain
polyunsaturated fatty acids, as strict low protein/Met
diets are usually deficient in essential fatty acids.
Separate supplements could be considered if they are
not included in the L-AA supplement. There are no
reports of deficiency in CBS deficiency.
Betaine treatment
Role of betaine (statement #26: grade of recommendation
C-D)
Betaine should be considered as adjunctive treatment in pa-
tients who cannot achieve target levels of Hcy by other means.
Betaine (N,N,N-trimethylglycine) is formed in the
body from choline and small amounts are present in the
normal diet (Zeisel et al 2003). It lowers Hcy concentra-
tions in CBS deficiency by donating a methyl group and
converting Hcy to Met (Komrower et al 1979; Smolin
et al 1981; Wilcken et al 1983, 1985; Singh et al 2004).
Betaine may also act as a chemical chaperone and correct
partial mis-folding of CBS mutants (Bourot et al 2000;
Diamant et al 2001, 2003; Kopecka et al 2011). Betaine
can increase cysteine levels (Benevenga 1984; Wilcken
et al 1985) but this is probably secondary to decreased
protein bound Hcy.
Betaine treatment alone seldom achieves target Hcy
levels in patients with pyridoxine-unresponsive CBS de-
ficiency. Studies of CBS-deficient mice gave similar re-
sults (Gupta et al 2016). This may be because betaine
treatment raises the Met concentration. Individuals with
plasma Met concentrations greater than 80 μmol/L re-
spond less well to betaine (Sakamoto and Sakura 2003),
though in practice some response is usually seen. For
these reasons, betaine is best used as adjunctive treat-
ment in patients who are partially responsive to pyri-
doxine or who are on dietary treatment but cannot
achieve good control.
Recommended betaine doses (statement #27: grade
of recommendation C-D)
Patients’ responses to betaine are variable and optimal doses
have to be individualised. For children, the initial betaine
dose is 50 mg/kg twice daily. For adults, the starting dose is
3 grams twice a day. The dose and frequency are adjusted
according to response. There is unlikely to be any benefit in
exceeding a dose of 150-200 mg/kg/day.
The published doses of betaine vary and very few studies
are consistent. Betaine has a half-life of 14 hours so twice
daily dosing is adequate (Schwahn et al 2003).
In children, the initial dose is 100 mg/kg/day, divided into
twice daily doses, and then adjusted according to response
(typically increased weekly by 50 mg/kg increments).
Studies based on pharmacokinetic and pharmacodynamic
modelling after single doses of 50-100 mg/kg betaine suggest
there is unlikely to be any additional benefit from using doses
higher than 150-200 mg/kg/day (Matthews et al 2002;
Schwahn et al 2003).
The maximum licensed dose is 3 grams twice daily and this
is the usual dose in adults but higher doses have sometimes
been used with anecdotal evidence of biochemical benefit.
Side effects of betaine (statement #28: grade
of recommendation C-D)
Generally betaine is well tolerated and safe. Higher doses
have been associated with a fishy odor. Cerebral edema is a
very rare side effect.
Betaine is generally safe but some people dislike the taste
and compliance may be poor (Walter et al 1998). It can result
in a fishy odor (Manning et al 2012). This is probably due to
inadequate activity of flavin containingmonooxygenase 3 and
may respond to riboflavin (Manning et al 2012).
Acute cerebral edema has been reported in two CBS
deficient patients treated with betaine. The plasma Met
concentration was above 2000 μmol/L in one patient
(Yaghmai et al 2002) and 1190 μmol/L in the other pa-
tient (Devlin et al 2004). In both patients, problems re-
solved after withdrawing betaine and lowering the plasma
Met concentration. Two other patients treated with betaine
have developed similar white matter abnormalities with-
out evidence of raised intracranial pressure; their plasma
Met concentrations were 904 and 1282 μmol/L. One pa-
tient made a full recovery after the plasma Met decreased
(Sasai et al 2015); neurological deficits persisted in the
other patient, who was encephalopathic for more than
2 months before the plasma Met was lowered
(Vatanavicharn et al 2008). A number of other CBS defi-
cient patients on betaine treatment have had Met levels
above 1000 μmol/L and have not experienced cerebral
edema. Cerebral edema has also been seen in a few non-
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CBS-deficient patients with high levels of Met. Further
research is required but the current recommendation is
to avoid Met levels above 1000 μmol/L in patients treated
with betaine.
Monitoring (statement #29: grade of recommendation D)
Monitoring of plasma tHcy, AA, folate and vitamin B12 is
recommended in all patients. The frequency depends on the
severity of CBS deficiency, treatment, age and clinical condi-
tion of the patient. These factors also determine the need for
additional monitoring; for example, patients on dietary treat-
ment require regular nutritional assessment.
Total homocysteine, plasma AAs (including Met), vitamin
B12 and folate should be monitored regularly in all patients
with CBS deficiency. There is, however, little evidence
concerning the optimal frequency of monitoring. This will
vary depending on the severity of the disorder (e.g. pyridox-
ine-responsiveness), the patient’s treatment, compliance, age
and previous complications (e.g. thrombosis). In adult patients
who are fully pyridoxine-responsive it may be adequate to
monitor tHcy levels every six months. In contrast, in children
on dietary treatment for pyridoxine-unresponsive CBS defi-
ciency, tHcy and Met will need to be monitored much more
frequently.
The method of analysis may also influence the frequency
of analysis. If tHcy is monitored in DBS sent in from home, it
is reasonable to request samples every week during infancy
(as in PKU) but this technique is not yet widely available. In
most centres, patients will need to attend a hospital for tHcy
monitoring samples to be taken from liquid blood and samples
will be taken less often.
The serum vitamin B12 and folate levels should be mea-
sured annually; if the vitamin B12 is low, an intramuscular
supplement is generally given and levels repeated every 3-6
months thereafter.
Patients on dietary treatment require regular nutritional as-
sessment and additional tests, depending on the patient’s age
and clinical condition. Some suggestions are listed in Table 3.
One should consider annual monitoring of the blood count,
renal profile, liver profile, copper, zinc and selenium, vitamin
D and essential fatty acids as well as plasma AAs. There is no
specific evidence relating to CBS deficiency but there are
reports of micronutrient deficiency in patients on similar die-
tary treatment for PKU. Tests should be done more frequently
if there is poor adherence to diet, inadequate medical food
consumption, poor growth or clinical evidence of malnutri-
tion. More extensive monitoring can be done if clinically in-
dicated. Supplements should be given if nutritional deficien-
cies are identified.
Bone density scans (DEXA) should be done every 3-5
years from adolescence with additional scans in individuals
who have frequent fractures and/or low vitamin D levels.
Neuroimaging (MRI) is only indicated in individuals who
have abnormal neurological signs.
Complications of CBS deficiency
The major complications of CBS deficiency can be
categorised into four groups: ophthalmological, skeletal, neu-
rological and cardiovascular/haematological. Rarer complica-
tions include pancreatitis and spontaneous pneumothorax
(Franchis et al 1998). The complications can be prevented
by treatment; once they have occurred, they are often irrevers-
ible but interventions can minimise further problems.
Ophthalmological complications and interventions (statement
#30: grade of recommendation C)
Ophthalmological complications in CBS deficiency are com-
mon and include myopia, ectopia lentis and associated
complications (glaucoma, retinal detachment). The true fre-
quency is unknown. Ectopia lentis may be the first and only
sign of CBS deficiency. Early diagnosis and lifelong treatment
with good biochemical control can prevent this complication.
Loss of biochemical control can be associated with progres-
sion of ocular complications, even in adults, and early signs
include the development of myopia and iridodonesis.
Restoration of biochemical control can halt progression of
these complications. Regular assessment by an ophthalmolo-
gist is recommended.
Ectopia lentis is the most consistent clinical finding in CBS
deficiency and many cases have been diagnosed because of
this (Mudd et al 1985). Lens dislocation is extremely rare in
the first 2 years of life but, without treatment, 85 % of pyri-
doxine non-responders have dislocated lenses by 12 years of
age. Lens dislocation also occurs in many pyridoxine-
responsive patients, including adults.
Dislocation of the lens results from disruption of the zonu-
lae fibres, which are thickened and abnormal in CBS deficien-
cy. Dislocation is usually bilateral and often occurs inferiorly
or nasally, or both (Ramsey et al 1972; Ramsey and Dickson
1975; Yap 2000). Iridodonesis is the quivering of the iris
caused by moving the eyeball and is a sign of the loosening
of the lens.
Disruption of the zonulae fibres also leads to increased
curvature of the lens and thereby to lenticular myopia and
astigmatism. High myopia >5D is extremely rare in children
under 5 years and probably affects under 2 % of adults
(Mohindra and Held 1981). Lenticular subluxation due to
homocystinuria should be suspected in these patients if there
is no evidence of axial myopia on fundoscopy and corneal
curvature is normal. Rapid progression of myopia also sug-
gests a lenticular cause, as does high non-corneal astigmatism
with subnormal visual activity (Cruysberg et al 1996).
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In addition tomyopic astigmatism, lens dislocation can lead to
retinal detachment, strabismus and cataracts. Anterior dislocation
of the lens can cause acute pupillary block glaucoma (Mudd et al
1995). Complete lens dislocation is associated with increased
ocular axial length, which may be an attempt to compensate for
the blurred vision (Mulvihill et al 2004).
Skeletal complications and interventions (statement #31:
grade of recommendation C-D)
Skeletal complications in CBS deficiency are common and
include long bone overgrowth and premature osteoporosis.
The true frequency is unknown. Early diagnosis and lifelong
treatment with good biochemical control can prevent this
complication. Loss of biochemical control can be associated
with progression of skeletal complications and early signs
include exaggerated growth velocity in children. Regular
DEXA scans are recommended from adolescence unless clin-
ically indicated earlier. Osteoporosis should be managed by
an appropriate specialist.
Skeletal changes are common but they are often absent in
pyridoxine-responsive individuals. There are no abnormalities
at birth (Sorsby et al 1960; Smith 1967; Mudd et al 1985) and
they are rare in infants or very young children. Genu valgum
and pes cavus are usually the first signs. As puberty nears,
dolichostenomelia becomes evident and the limbs grow out
of proportion to the trunk. Anterior chest wall deformities,
such as pectus excavatum or carinatum, and kyphosis or
scoliosis may be present (Brenton et al 1972; Carson 1982).
The facial appearance may be altered by prominence and pro-
trusion of the upper teeth due to overcrowding and the palate
is almost always high arched (Mudd et al 1995; Brenton et al
1972). These skeletal manifestations give older patients an
appearance similar to that of Marfan syndrome (Smith 1967;
Morreels et al 1968; Beals 1969; Brenton et al 1972;
Schedewie et al 1973; Boers et al 1983, 1984; Mudd et al
1985) but CBS deficiency can be distinguished by the pres-
ence of osteoporosis (Carson 1982).
Osteoporosis, especially of the spine, is the most consistent
skeletal abnormality. In the largest review, 70 % of untreated
pyridoxine-unresponsive patients developed spinal osteoporo-
sis by 16 years of age (Mudd et al 1985). This may, however,
be an overestimate as osteoporosis was not defined according
to current criteria (ISCD, 2013, http://www.iscd.org/official-
positions/2013-iscd-official-positions-pediatric). Spinal
osteoporosis also occurs in many pyridoxine responsive
cases, usually at a later age (Mudd et al 1985). Early diagnosis
and effective treatment reduce the risk of osteoporosis (Yap
and Naughten 1998; Lim and Lee 2013).
Osteoporosis may lead to vertebral collapse (Schimke et al
1965; Brenton 1977) and scoliosis, though the latter has also
been reported in the absence of osteoporosis. DEXA scanning
should routinely be performed every 3-5 years from adoles-
cence unless there is a clinical indication to do this earlier
(such as recurrent fractures). Due to the sensitivity of the test,
there is little point in repeating this more frequently than every
Table 3 Monitoring
recommendations Area Tests Frequency
Anthropometry Height & weight Every clinic visit
Dietary Dietary intake analysis Every clinic visit if on
dietary treatment
Biochemical–metabolic control tHcy, Met See text
Nutritional Vitamin B12, folate At least annually
Blood count, albumin, plasma AA, ferritin,
zinc, 25-hydroxyvitamin D
At least annually if on
dietary treatment
Selenium,
essential fatty acids
If concerns about intake
Neurodevelopmental/
neurological
Clinical examination Annually
MRI/EEG Only if new CNS symptoms
Ophthalmological Eye examination At least annually
Neuropsychological ffunction IQ At least every 5 years during
childhood
Psychological Clinical psychology or psychiatric
assessment
As required
Bone density DEXA Every 3-5 years from ado-
lescence—unless clini-
cally indicated earlier
Cardiovascular Lipid profile, cardiovascular risk factor
review
Once in childhood,
annually in adulthood
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2 years. In patients with reduced bone mineral density, it is
particularly important to check vitamin D status and dietary
calcium intake and to encourage weight-bearing exercise.
Cardiovascular complications and interventions (statement
#32: grade of recommendation C-D)
Venous thromboembolic complications are common in un-
treated or poorly controlled CBS deficiency. In untreated pyr-
idoxine unresponsive patients, the risk may be as high as 50%
by 30 years of age. The frequency in pyridoxine responders is
unknown. It may be the first and only sign of CBS deficiency.
Early diagnosis and lifelong treatment with good biochemical
control can prevent this complication. Prevention of dehydra-
tion is important. Patients who are poorly controlled or have
had a vascular event may warrant additional treatment with
anti-platelet drugs or anticoagulants, according to local
guidelines.
Vascular complications are common in untreated or poorly
controlled CBS deficiency and include venous thrombosis and
arterial thrombosis. Venous thrombosis is the more common. In
the largest published series of untreated patients, 50 % of the
vascular complications were deep venous thrombosis (a quarter
of which were associated with pulmonary embolism); stroke
(including cerebral venous sinus thrombosis) comprised 32 %
of the vascular complications, peripheral arterial disease 11 %
and myocardial infarction only 4 % (Mudd et al 1985).
It has been suggested that the risk of thrombosis in
homocystinuria depends largely on whether patients also have
the factor VLeidenmutation (Mandel et al 1996) but thiswas not
supported by subsequent studies (Kluijtmans 1998, Yap 1999,
Gaustadnes 2002). The value of testing for such thrombophilic
mutations is, therefore, unknown and possibly low.
In patients with CBS deficiency, lowering the plasma tHcy
is the single most important factor in reducing the risk of
thromboembolic disease (Wilcken and Wilcken 1997; Yap
2003). Additional preventive treatment should be used if there
are other risk factors for thromboembolism, such as immobil-
ity due to surgery or travel (Special management issues).
Dehydration and infection increase the risk of venous throm-
bosis, particularly in children, by increasing blood viscosity
and all the reports of cerebral venous sinus thrombosis in
neonates with CBS deficiency have occurred in the context
of severe infections and dehydration (Cardo et al 1999; Karaca
et al 2014). It is, therefore, important to ensure patients with
CBS deficiency are well hydrated at all times and especially
when unwell and during anaesthesia and surgery (see
Management of surgery and anaesthesia (statement #38: grade
of recommendation C-D)).
There is some evidence that there may be increased platelet
activation in patients with CBS deficiency, even on treatment
(DiMinno et al 1992). Treatment with antiplatelet drugs such
as aspirin, dipyridamole or clopidogrel may, therefore, be
indicated in patients who are poorly controlled or have already
had a vascular event. Coumarin anticoagulants may be appro-
priate for patients who have had a venous thrombosis.
Acute stroke can occur in CBS deficiency patients due to
arterial thrombosis/embolism and carotid artery disease/
dissection but it is usually due to cerebral venous sinus throm-
bosis (Mudd 1985; Hou and Wang 1994; Kelly et al 2003;
Weiss et al 2006; Granel et al 2009). It is important to lower
the plasma Hcy level, particularly if the stroke is the present-
ing feature (Wilcken and Wilcken 1997; Yap 2003).
Anticoagulation carries the risk of bleeding into an
oedematous brain, especially if there is hypertension, and
needs to be decided on an individual basis. In children, par-
ticular care should be taken to ensure adequate hydration and
to treat any underlying infection (Cardo et al 1999).
Neurological and psychological complications
and interventions (statement #33: grade of recommendation
D)
Neurological complications include seizures and movement
disorders. Treatment can be difficult and should involve a
neurologist. Cerebral white matter abnormalities have been
reported in a few patients treated with betaine but there is no
evidence to support routine MRI or EEG surveillance, in the
absence of symptoms. Psychological and psychiatric
complications, including psychosis and depression, are com-
mon in patients with CBS deficiency.
Neurological complications include seizures and move-
ment disorders in addition to strokes. Seizures occur in 20 %
of untreated pyridoxine-unresponsive patients by 12 years of
age. EEG abnormalities may be more common, reflecting un-
derlying brain disease. There is no evidence to support routine
EEGmonitoring in the absence of symptoms (del Giudice et al
1983; Mudd et al 1985; de Franchis et al 1998; Buoni et al
2003). There are several case reports of movement disorders
which are not due to basal ganglia infarction, including
polymyoclonus, dystonia and parkinsonism. Some of these
patients have responded to L-DOPA therapy but others have
not and this drug should be used with caution as it can raise
Hcy levels (Kempster et al 1988; Awaad et al 1995; Keskin
and Yurdakul 1996; Burlina et al 2002; Ekinci et al 2004;
Sinclair et al 2006).
Cerebral white matter abnormalities have been reported in
a few patients treated with betaine, associated with high plas-
ma Met concentrations (see Side effects of betaine (statement
#28: grade of recommendation C-D)). Routine MRI surveil-
lance is not, however, recommended in patients with CBS
deficiency unless they have neurological symptoms (Keskin
and Yalcin 1994; Ekinci et al 2004; Vatanavicharn et al 2008;
Brenton et al 2012).
Many psychological and psychiatric conditions are over-
represented in patients with CBS deficiency. These include
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psychosis, obsessive-compulsive disorder, depression and
behaviour/personality disorders (such as aggression and drug
or alcohol abuse) (Grobe 1980; Bracken and Coll 1985;
Abbott et al 1987; de Franchis et al 1998; Hidalgo et al 2013).
Fertility, contraception and pregnancy in CBS deficiency
Fertility (statement #34: grade of recommendation C-D)
There is no compelling evidence that CBS deficiency affects
fertility. There is also no convincing evidence that CBS defi-
cient patients have an increased risk of fetal loss or fetal
malformations.
The only published studies looking at fertility in CBS de-
ficiency have been in mice. These showed changes in the
estrus cycle, possible oocyte differences, increased fetal loss
and lactation disturbances (Guzman et al 2006; Nuno-Ayala
et al 2010). Mouse studies also indicate that CBS is important
(via its role in H2S production) in the maintenance of labour
(You et al 2011).
Increased malformations have not been reported in the chil-
dren of womenwith CBS deficiency (Levy et al 2002). It is more
difficult to analyse fetal loss because it is not always reported and
early losses are not always recognised. Although data from sev-
eral studies link miscarriage to increases in Hcy (Owen et al
1997), studies in treated patients with CBS deficiency have not
shown an increased risk of miscarriage compared to the general
population (Mudd et al 1985).
Males are fertile and in one study 21 males sired 34 fetuses
of which 33 were healthy and one spontaneously aborted
(Mudd et al 1985).
Contraception (statement #35: grade of recommendation D)
Estrogen containing contraceptives should be avoided due to
the increased risk of thrombosis.
This recommendation was originally made when contra-
ceptives had a relatively high estrogen content (McCully
1975; Grobe 1978). It is unknown whether lower dose estro-
gen preparations are safe, for example in well-controlled pyr-
idoxine-responsive CBS deficiency.
Pregnancy, delivery and peripartum management (statement
#36: grade of recommendation C-D)
Pregnancy, delivery and the post-partum period pose an ad-
ditional risk of thrombosis in CBS deficient women.
Anticoagulant therapy in the form of low molecular weight
heparin is recommended during the third trimester (and may-
be throughout pregnancy) and for at least 6 weeks postpar-
tum. Met requirements often increase through pregnancy; it is
important that the dietary management is regularly reviewed
with frequent biochemical monitoring. After delivery, the Met
intake should be reduced to no more than pre-pregnancy
levels.
Thrombosis is a major risk for pregnant women with CBS
deficiency. Some women present for the first time with throm-
boses during pregnancy or the post-partum period (Calvert
and Rand 1995). The risk is particularly high for 6 weeks after
delivery, while the uterus is involuting: plasma Hcy concen-
trations are often high at this time despite treatment (Yap et al
2001a, b, c; Levy et al 2002). There are no studies of the
optimal timing or form of anticoagulation in CBS deficiency
but thrombophilia is considered in many thromboprophylaxis
guidelines. All patients should have anticoagulation for the
third trimester and continue it for 6 weeks post-partum; wom-
en with additional risk factors or a previous thrombosis should
usually have anticoagulation throughout pregnancy. Low mo-
lecular weight heparin is used most widely but subcutaneous
heparin has also been recommended (Calvert and Rand 1995;
Yap et al 2001a, b, c). Warfarin has also been used in the post-
partum period (Calvert and Rand 1995).
Management of CBS deficiency during pregnancy de-
pends on the phenotype. For example, individuals who
have pyridoxine-responsive CBS deficiency should re-
main on their pyridoxine through pregnancy; there is
some weak evidence that this improves outcomes, though
this is based on only a few patients (Mudd et al 1985;
Levy et al 2002). Adjuvant therapies may be necessary to
maintain adequate energy and protein intake and appro-
priate Hcy levels. Betaine has been used in pregnancy
without adverse effects (Yap et al 2001a, b, c; Pierre
et al 2006). All pregnant patients should receive folate
supplementation (at least 400 micrograms), along with
vitamin B12 if there is evidence of deficiency.
In pyridoxine unresponsive CBS deficient women, there is
an increasedMet requirement as the fetus grows. The aim is to
increase Met intake while still maintaining good biochemical
control (Yap et al 2001a, b, c). The WHO/FAO/UNU recom-
mend additional protein intake in pregnant women (0.5 g/day
in trimester 1, 8 g/day in trimester 2 and 25 g/day in trimester
3). Increased L-AA supplements may be required if the in-
crease in natural protein tolerance is insufficient to meet these
requirements. It is important that the dietary management is
regularly reviewed with frequent biochemical monitoring.
Zinc and selenium deficiencies have been found in some
women (Pierre et al 2006). Monitoring of fibrinogen as a sec-
ondary marker of coagulopathy can be helpful in patients with
poor control (Ritchie and Carson 1973; Yap et al 2001a, b, c).
After delivery, theMet intake should be reduced to nomore
than pre-pregnancy levels (Yap et al 2001a, b, c). However,
the WHO/FAO/UNU protein requirements during lactation
recommend an additional 20 grams protein/day, falling to
12.5 grams per day after 6 months. Some of this will need to
be given as Met-free L-AA supplements, guided by biochem-
ical monitoring.
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Special management issues
Management of intercurrent illness (statement #37: grade
of recommendation D)
During intercurrent illness, patients should continue their reg-
ular treatment (such as pyridoxine, betaine, their L-AA mix-
ture and adequate energy). Dehydration and immobilization
should be avoided to reduce the risk of thromboembolic
disease.
Venous thrombosis is the main acute concern and the risk
of this should be minimised by avoiding dehydration or im-
mobilisation. Intractable vomiting may necessitate intrave-
nous fluids.
None of the treatments for homocystinuria need to be
stopped during intercurrent illnesses. Some increase in Hcy
during illness is to be expected due to catabolism and should
not be a concern for isolated, short illnesses. More frequent
nutritional monitoring may be needed in patients on dietary
treatment who have prolonged or recurrent illnesses.
Management of surgery and anaesthesia (statement #38:
grade of recommendation C-D)
Surgery and anaesthesia pose an additional risk of thrombosis
in CBS deficiency. Biochemical control, dietary management
and nutrition should be optimised before elective procedures.
Hydration should be maintained with intravenous fluids.
Standard anti-thrombotic measures such as elastic stockings,
pneumatic leg compression systems and early mobilization
should be followed during and after surgery. Low molecular
weight heparin is recommended in cases of prolonged immo-
bilisation. Nitrous oxide increases Hcy concentrations and
should be avoided.
There are multiple reports of previously diagnosed and
undiagnosed patients with thomboses during surgery
(Carson et al 1965; Morreels et al 1968; Elkington et al
1973; Harker et al 1974; Grieco 1977; Harker and Scott
1977; Mudd et al 1985; Arbour et al 1988). These can be fatal
(Carson et al 1965; Mudd et al 1985), if not aggressively
treated. The risk is even higher in arteriography/venography.
In a historical cohort of 241 major surgical procedures there
were 14 post-operative thromboembolic events with four be-
ing fatal (Mudd et al 1985).
Although there have been no clinical trials, there is no
question that control should be optimised prior to elective
surgery and maintaining hydration is important. One should
also consider consulting a haematologist and an anaesthetist
before elective procedures. Historically dipyridamole, aspirin
and warfarin have been used to prevent thromboembolism
(Harker et al 1974; Schulman et al 1978) but low molecular
weight heparin prophylaxis is now recommended. Early post-
operative mobilisation and inflation compression stockings
are also recommended (Lowe et al 1994; Asghar and Ali
2012), as in other states associated with an increased risk of
deep venous thrombosis.
Nitrous oxide inactivates cobalamin, thereby inhibiting
methionine synthase. Rises in Hcy have been reported follow-
ing its use during anaesthesia. Nitrous oxide should be
avoided in patients with CBS deficiency and, particularly, if
there is vitamin B12 deficiency, when it can cause subacute
combined degeneration of the cord.
Precautions for travel (statement #39: grade
of recommendation D)
Standard measures for preventing thrombosis are recom-
mended for travel.
There are no publications concerning travel and
homocystinuria. Guidelines for patients who have had a ve-
nous thromboembolism are the same as for patients with
thrombophilia—i.e. prophylactic low molecular weight hepa-
rin (Guyatt et al 2012). There are no guidelines for patients
who have not had thromboembolism, but encouraging mobil-
ity and maintaining hydration is appropriate (Biasiutti and
Lammle 1994).
Outcome (statement #40: grade of recommendation C-D)
Without treatment, life expectancy is markedly reduced in
pyridoxine-unresponsive patients. The life expectancy of
pyridoxine-responsive patients is uncertain due to under-
ascertainment in studies of this group. With early life-long
adequate treatment, outcomes are generally good, although
the very long-term outcomes are not yet known. Late teen-
agers and young adults are at high risk of non-compliance
and complications, including death. Outcomes are determined
primarily by pyridoxine responsiveness, adequacy of treat-
ment and age of detection.
If untreated, the prognosis of pyridoxine-unresponsive
CBS deficiency is bleak (Carson et al 1965; Schimke et al
1965; Mudd et al 1985). The consequences of untreated, or
partially treated, CBS deficiency include thromboembolic
events, mental retardation, ocular and skeletal manifestations.
An international study that documented the natural history of
629 untreated CBS patients showed that the risk of complica-
tions increases with age, and that pyridoxine-unresponsive
patients are more severely affected (Mudd et al 1985).
Pyridoxine responsive patients had significantly better mental
capacities (n = 107, mean 79) than pyridoxine-unresponsive
patients (n = 115, mean 57). The results of this study, however,
were subject to ascertainment bias as milder cases, associated
with pyridoxine responsiveness, were probably under-
represented (Skovby et al 2010). Pyridoxine-responsive pa-
tients who present with thromboembolism as adults usually
have a normal IQ and no other complications.
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Long-term treatment, with good biochemical control, pre-
vents complications from developing but it does not reverse
complications already present. Moreover, loss of biochemical
control at any age is associated with serious complications,
whichmay be life-threatening. Thus, for pyridoxine unrespon-
sive patients, optimal outcomes require NBS and treatment
shortly after birth. No complications were observed in 15 such
patients from Ireland, aged up to 25 years, whose lifetime
median fHcy was maintained below 11 μmol/L (Yap and
Naughten 1998). They all had excellent vision, with full scale
IQ ranging from 84-120 (mean 105.8) in 13 of the early treat-
ed and compliant patients (Yap et al 2001a, b, c). These pa-
tients are now aged up to 43 years and outcomes remain good
in those whose plasma fHcy has remained less than 11 μmol/L
with only brief rises above this (Crushell E and O’Sullivan S,
personal communication). Similar findings were reported in
11 pyridoxine unresponsive, early treated patients from
Manchester, aged up to 25 years (Walter et al 1998), with full
scale IQ ranging from 84-117 (median 100). The outcome for
pyridoxine non-responsive patients diagnosed clinically (and
therefore later) was poor with a median IQ of 58 (n = 2).
Quality of life (statement #41: grade of recommendation
D)
There are no data regarding the quality of life from the
patient’s or parent’s point of view and this area requires fur-
ther study.
A systematic search of the PubMed and Cochrane data-
bases using the terms Bquality of life^ combined with BCBS
deficiency^ or Bhomocystinuria^ identified no publication ad-
dressing this. There are also very few publications concerning
employment or independence. Bhat documented the social
outcome in treated individuals attending one metabolic centre
in the UK (Bhat et al 2005). Only five out of 33 were detected
on newborn screening. Marginally higher employment rates
were found in the pyridoxine-responsive group, and more of
the pyridoxine responsive patients were in long term relation-
ships. This was, however, subject to ascertainment bias, as the
questionnaire was completed by patients.
Biochemical and physical outcome parameters are gener-
ally used for patients with inborn errors of metabolism but
quality of life (QoL) should also be assessed (Zeltner et al
2014). Psychosocial factors such as coping strategies predict
health-related QoL in patients with chronic disease more pre-
cisely than physical parameters (Cohen and Biesecker 2010).
Moreover, QoL assessments are essential for an overall esti-
mation of treatment success (Simon et al 2008).
For patients with metabolic diseases, major concerns in-
clude dietary restrictions, blood sampling, social stigmatiza-
tion and exclusion (Zeltner et al 2016). Delay in diagnosis is a
major concern for many families as accurate diagnosis is the
first step to improving the care for those living with a rare
disease (eurordis.org/IMG/pdf/voice_12000_patients/
EURORDISCARE.FULLBOOKKr.pdf) (retr ieved
March 2015).
The impact on families should not be underestimated. The
parents of a child with a metabolic disorder are likely to have
lower health related QoL than parents of children with other
chronic diseases (Hatzmann et al 2009). A study of Australian
families caring for children with genetic metabolic disorders
found they were adversely affected by delays in diagnosis,
poor access to peer support groups and lack of psychological
support (Anderson et al 2013).
Research is needed to identify which strategies are most
effective in improving QoL for patients with homocystinuria.
Conclusions
These guidelines are based on the best data currently available
concerning the diagnosis, biochemistry, complications and
management of CBS deficiency. Unfortunately, many of our
recommendations are grade D, due to a lack of high grade
published evidence. The guidelines should be used to identify
the areas in which data are lacking and to facilitate the design
of international collaborative studies, using the same diagnos-
tic measures and therapies. We envisage revising the guide-
lines in 5 years to incorporate data from such studies and other
advances. The ultimate goal of these guidelines is to improve
the lives and health of patients with pyridoxine-responsive
and -unresponsive CBS deficiency now and in the future.
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